CCHF in pregnancy linked to 28.8% maternal death and 57.4% fetal loss in meta-analysis
“Ribavirin treatment during the third trimester was associated with lower observed maternal mortality rates (odds ratio 0.33, 95% CI 0.13-0.84; p = 0.031).”
Where these numbers come from
The publication
A meta-analysis of 55 pregnancies found that Crimean-Congo hemorrhagic fever (CCHF) was associated with a 28.8% maternal mortality rate and a 57.4% fetal loss rate. Ribavirin treatment during the third trimester was associated with lower observed maternal mortality rates, with an odds ratio of 0.33 (95% CI 0.13-0.84; p = 0.031).
Who the findings apply to
The analysis included 55 pregnancies with CCHF identified through systematic database searches and direct collaboration with centers in CCHF-endemic areas.
Data were harmonized from published and unpublished case reports, including clinical, laboratory, obstetric, treatment, and outcome information.
Why this matters
The study synthesizes patient-level data from published and unpublished cases to address limited evidence on CCHF during pregnancy. The findings highlight gestational age-specific risks, with maternal mortality increasing in the third trimester and fetal loss highest in the first trimester. These results support the need for standardized management protocols and strengthened CCHF surveillance during pregnancy in endemic regions.
What the study found
The maternal mortality rate was 28.8% (15/52), and fetal loss occurred in 57.4% (31/54) of cases.
Maternal mortality rates increased with advancing gestation, reaching 31.3% in the third trimester, but fetal loss was highest (85.7%) in the first trimester.
Ribavirin treatment during the third trimester was associated with lower observed maternal mortality rates (odds ratio 0.33, 95% CI 0.13-0.84; p = 0.031).
What the result does not establish
Evidence remains limited to heterogeneous case reports, which may introduce variability in data quality and comparability.
The association between ribavirin treatment and lower maternal mortality is observational and does not establish causation.
Authors’ conclusion
“Ribavirin treatment during the third trimester was associated with lower observed maternal mortality rates (odds ratio 0.33, 95% CI 0.13-0.84; p = 0.031). Our findings highlight gestational age-specific risks of CCHF and support the need for standardized management protocols and strengthened CCHF surveillance during pregnancy in endemic regions.”
Study and sources
Meta-analysis of Maternal and Fetal Outcomes of Crimean-Congo Hemorrhagic Fever during Pregnancy
Systematic review / meta-analysis · Emerging infectious diseases · 2026-10-01
Sources and limitations
- PubMed record PMID 42810996 (PubMed / NLM · 2026-10-01)
Related briefings
Follow ENCLAI News
Get new briefings in your news reader. No ENCLAI account needed.
The daily disease brief
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.


